Citations

Citations to this article as recorded by  

• Obesity management from the perspectives of people living with obesity in Canada: A mixed‐methods study
  David C. W. Lau, Ian Patton, Reena Lavji, Adel Belloum, Ginnie Ng, Renuca Modi
  Diabetes, Obesity and Metabolism.2024; 26(4): 1529.     CrossRef
• Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure
  Marissa Morris-Murray, Marie Frazzitta
  Journal of Managed Care & Specialty Pharmacy.2024; 30(10-b Suppl): S30.     CrossRef
• Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
  André J Scheen
  Expert Review of Clinical Pharmacology.2023; 16(11): 1053.     CrossRef

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by  

• Drug‐related sarcopenia as a secondary sarcopenia
  Masafumi Kuzuya
  Geriatrics & Gerontology International.2024; 24(2): 195.     CrossRef
• Exercise induces tissue-specific adaptations to enhance cardiometabolic health
  Stephen P. Ashcroft, Ben Stocks, Brendan Egan, Juleen R. Zierath
  Cell Metabolism.2024; 36(2): 278.     CrossRef
• Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes
  Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki
  Obesity Pillars.2024; 9: 100098.     CrossRef
• Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
  Joseph Henson, Aikaterina Tziannou, Alex V. Rowlands, Charlotte L. Edwardson, Andrew P. Hall, Melanie J. Davies, Thomas Yates
  Diabetes, Obesity and Metabolism.2024; 26(4): 1355.     CrossRef
• The Current Landscape of Pharmacotherapies for Sarcopenia
  Gulistan Bahat, Serdar Ozkok
  Drugs & Aging.2024; 41(2): 83.     CrossRef
• Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
  ELISSA DRIGGIN, PARAG GOYAL
  Journal of Cardiac Failure.2024; 30(4): 610.     CrossRef
• Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
  Daniel Lee, Jacqueline Capeau
  AIDS.2024; 38(4): 603.     CrossRef
• Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
  Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas
  Obesity.2024; 32(5): 840.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
  David Ni, Peter Kokkinos, Eric S Nylen
  Military Medicine.2024;[Epub]     CrossRef
• Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
  Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, Timo D. Müller
  Diabetes Therapy.2024; 15(5): 1069.     CrossRef
• GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome
  Michael L. Fragner, Manish A. Parikh, Kaedrea A. Jackson, Michal Laniado Schwartzman, William H. Frishman, Stephen J. Peterson
  Cardiology in Review.2024;[Epub]     CrossRef
• The effects of myosteatosis on skeletal muscle function in older adults
  Kathleen Dondero, Ben Friedman, Julie Rekant, Rian Landers‐Ramos, Odessa Addison
  Physiological Reports.2024;[Epub]     CrossRef
• Preservation of healthy lean body mass and function during weight loss
  T. J. Wilkinson, D. Papamargaritis, J. A. King, J. A. Sargeant, C. Sutcliffe, L. A. Baker, S. Taheri, T. Yates, M. J. Davies
  Clinical Obesity.2024;[Epub]     CrossRef
• The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
  Emanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, Sten M.M. van Beek, Nodi Dehvari, Carina Halleskog, Hamza M. Bokhari, Dana S. Hutchinson, Seungmin Ham, Laura J. Humphrys, Nicola C. Dijon, Aikaterini Motso, Anna Sandstrom, Evelyn Zacharewicz, I
  Molecular Metabolism.2024; 85: 101931.     CrossRef
• Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery
  Tom Doyle
  Bone & Joint 360.2024; 13(3): 12.     CrossRef
• Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
  Guillaume Mahé, Victor Aboyans, Emmanuel Cosson, Kamel Mohammedi, Gabrielle Sarlon-Bartoli, Damien Lanéelle, Tristan Mirault, Patrice Darmon
  Cardiovascular Diabetology.2024;[Epub]     CrossRef
• Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
  Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld
  Diabetes, Obesity and Metabolism.2024; 26(S4): 16.     CrossRef
• Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
  Paola Pantanetti, Giovanni Cangelosi, Sara Alberti, Sandra Di Marco, Grazia Michetti, Gianluca Cerasoli, Marco Di Giacinti, Silvia Coacci, Nadia Francucci, Fabio Petrelli, Giuseppe Ambrosio, Roberto Grinta
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging
  Zainab Ridha, Sabrina Guillen Fabi, Raheel Zubar, Steven H Dayan
  Aesthetic Surgery Journal.2024;[Epub]     CrossRef
• Second Generation Anti-Obesity Medications
  Sri Nikhita Chimatapu, Steven D. Mittelman, Vibha Singhal
  Current Pediatrics Reports.2024;[Epub]     CrossRef
• Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
  Oluwaseun Anyiam, Bethan Phillips, Katie Quinn, Daniel Wilkinson, Kenneth Smith, Philip Atherton, Iskandar Idris
  Clinical Nutrition.2024; 43(8): 1907.     CrossRef
• Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs
  Sandra Christensen, Katie Robinson, Sara Thomas, Dominique R. Williams
  Obesity Pillars.2024; 11: 100121.     CrossRef
• Gut-muscle communication links FGF19 levels to the loss of lean muscle mass following rapid weight loss
  Jordan Wean, Salisha Baranwal, Nicole Miller, Jae Hoon Shin, Robert W. O'Rourke, Charles F. Burant, Randy J. Seeley, Amy E. Rothberg, Nadejda Bozadjieva-Kramer
  Diabetes & Metabolism.2024; 50(5): 101570.     CrossRef
• The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study
  Takeshi Oyanagi, Shin Kawanabe, Hidekazu Tsukiyama, Ami Nishine, Yuta Nakamura, Tomoko Nakagawa, Mayuko Kanou, Juri Kubota, Shingo Tsunemi, Kenichi Yokota, Masakatsu Sone
  Diabetes Therapy.2024;[Epub]     CrossRef
• Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
  Lidiya Kukova, Kashif M. Munir, Ahmed Sayeed, Stephen N. Davis
  Expert Opinion on Drug Metabolism & Toxicology.2024; : 1.     CrossRef
• Sarcopenia
  Avan A. Sayer, Rachel Cooper, Hidenori Arai, Peggy M. Cawthon, Marie-Josiane Ntsama Essomba, Roger A. Fielding, Miranda D. Grounds, Miles D. Witham, Alfonso J. Cruz-Jentoft
  Nature Reviews Disease Primers.2024;[Epub]     CrossRef
• Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps
  Robert L. Dubin, Steven B. Heymsfield, Eric Ravussin, Frank L. Greenway
  Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
• Geriatric Pharmacotherapy Case Series: Medications for Diabetes—A Focus on Secondary Stroke Prevention
  Sabrina Warren, Shayla McKee, Erin Yakiwchuk
  The Senior Care Pharmacist.2024; 39(10): 350.     CrossRef
• Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
  Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
  International Journal of Cardiology.2023; 370: 263.     CrossRef
• Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
  Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
  Obesity.2023; 31(1): 74.     CrossRef
• Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
  Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
  Diabetes, Obesity and Metabolism.2023; 25(4): 901.     CrossRef
• The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
  Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
  Obesity Reviews.2023;[Epub]     CrossRef
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
  Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
  Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies
  Diabetic Medicine.2023;[Epub]     CrossRef
• Cancer cachexia as a blueprint for treating obesity
  Nikolai P. Jaschke, Tilman D. Rachner
  Trends in Endocrinology & Metabolism.2023; 34(7): 395.     CrossRef
• The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
  Peter N. Benotti, Bruce R. Bistrian
  Surgery for Obesity and Related Diseases.2023; 19(9): 1075.     CrossRef
• Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
  Cody Rutledge, Angela Enriquez, Kevin Redding, Mabel Lopez, Steven Mullett, Stacy L. Gelhaus, Michael Jurczak, Eric Goetzman, Brett A. Kaufman
  Cardiovascular Drugs and Therapy.2023;[Epub]     CrossRef
• Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Cysteine‐lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose‐finding study
  Kathrine J. Vinknes, Thomas Olsen, Hasse Khiabani Zaré, Nasser E. Bastani, Emma Stolt, Anja F. Dahl, Roger D. Cox, Helga Refsum, Kjetil Retterstøl, Anders Åsberg, Amany Elshorbagy
  Diabetes, Obesity and Metabolism.2023; 25(11): 3161.     CrossRef
• Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review
  Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
  Drugs & Aging.2023; 40(8): 703.     CrossRef
• Introduction to the dietary management of obesity in adults
  Vivian Lee
  Clinical Medicine.2023; 23(4): 304.     CrossRef
• Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
  Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino
  Diabetes, Obesity and Metabolism.2023; 25(12): 3538.     CrossRef
• Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors
  Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi
  Circulation Journal.2023; 88(1): 10.     CrossRef
• Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
  Baris Afsar, Rengin Elsurer Afsar
  Clinical Nutrition.2023; 42(12): 2338.     CrossRef
• Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
  Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
  Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh
  Diabetes Therapy.2023; 14(12): 2015.     CrossRef
• Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Chengdong Xia, Yufeng Han, Chunhui Yin, Ruyue Geng, Zhenfei Liu, Yongle Du, Mingkun Yu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
  Thomas A. Wadden, Ariana M. Chao, Molly Moore, Jena S. Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M. Jakicic
  Current Obesity Reports.2023; 12(4): 453.     CrossRef
• Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
  Giuseppe Lisco, Olga Eugenia Disoteo, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Fabio Monzani, Emilio Jirillo, Renato Cozzi, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani
  Nutrients.2023; 16(1): 63.     CrossRef
• Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
  Sabine Kahl, Jennifer Pützer, Michael Roden
  Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
• Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
  Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
  Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
• Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
  Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
  Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
• Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
  Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
  Scientific Reports.2022;[Epub]     CrossRef
• Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
  Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
  Obesity Reviews.2022;[Epub]     CrossRef
• Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
  Expert Opinion on Drug Safety.2022; 21(10): 1315.     CrossRef
• Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
  Expert Opinion on Drug Safety.2022; 21(11): 1411.     CrossRef
• Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
  Lyse Bordier, Jean Doucet, Bernard Bauduceau
  Médecine des Maladies Métaboliques.2022; 16(5): 422.     CrossRef
• Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
  Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
  Nutrition.2022; 103-104: 111815.     CrossRef
• The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
  Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
  Medicines.2022; 9(9): 47.     CrossRef
• Distribution of lean mass and mortality risk in patients with type 2 diabetes
  Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
  Primary Care Diabetes.2022; 16(6): 824.     CrossRef
• Cardio-sarcopenia: A syndrome of concern in aging
  De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Type 2 diabetes
  Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
  The Lancet.2022; 400(10365): 1803.     CrossRef
• Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
  Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
  Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
  Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
• Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
  Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. le Roux
  Obesity.2021; 29(3): 529.     CrossRef
• Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
  Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
  BMJ Open.2021; 11(4): e045844.     CrossRef
• Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
  Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
  Cancer Prevention Research.2021; 14(5): 509.     CrossRef
• Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
  Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
  Journal of Translational Medicine.2021;[Epub]     CrossRef
• Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
  Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
  Nutrition & Diabetes.2021;[Epub]     CrossRef
• Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
  Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
  Drugs.2021; 81(11): 1243.     CrossRef
• Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
  Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
  The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
• Physical activity and exercise in the management of type 2 diabetes: where to start?
  Deirdre Harrington, Joe Henson
  Practical Diabetes.2021; 38(5): 35.     CrossRef
• Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
  
  New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
• Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
  Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
  Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
• Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
  Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
  Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
• Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
  Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
  Nutrients.2020; 12(2): 510.     CrossRef
• GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
  Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
  Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
• Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
  Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
  Aging Cell.2020;[Epub]     CrossRef